The Cochrane database of systematic reviews

How sample location and collection method affect detecting COVID-19 infection

Updated

Abstract

This review includes 106 studies with 60,523 sample pair comparisons assessing sampling methods for SARS-CoV-2 detection.

  • There is no evidence of a difference in sensitivity between gargle and nasopharyngeal samples when using RT-PCR.
  • Saliva collected from the deep throat showed a sensitivity increase of 10 percentage points compared to nasopharyngeal samples.
  • Saliva samples obtained through spitting, drooling, or salivating were, on average, 12 percentage points less sensitive than nasopharyngeal samples.
  • Nasal samples were 12 percentage points less sensitive than nasopharyngeal samples in detecting SARS-CoV-2.
  • Oropharyngeal samples demonstrated an average sensitivity that was 17 percentage points lower than that of nasopharyngeal samples.
  • For Ag-RDTs, there is no evidence of a difference in sensitivity between nasal samples and nasopharyngeal samples.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Jonathan J Deeks*: none known. Jacqueline Dinnes (JD)* is a Cochrane DTA Editor. She was not involved in the editorial process for this review. JD declares a grant from Evidence Synthesis Ireland, National University of Ireland, Galway, to supervise three fellows contributing to a Cochrane review of rapid antigen tests for Covid‐19; paid to the institution. JD declares publishing opinions on the topic: (1) Dinnes J, Davenport C. COVID‐19 rapid antigen testing strategies must be evaluated in intended use settings. Lancet. Regional Health, Western Pacific 2022;25:100542. DOI: 10.1016/j.lanwpc.2022.100542; (2) Deeks JJ, Dinnes J, Davenport C, Takwoingi Y, McInnes M, Leeflang MM, Cunningham J. Letter to the Editor regarding Peto T; UK COVID‐19 Lateral Flow Oversight Team: COVID‐19: Rapid antigen detection for SARS‐CoV‐2 by lateral flow assay. EClinicalMedicine 2021;38; (3) Dinnes J. COVID‐19 rapid antigen testing strategies require careful evaluation. EBioMedicine 2021;70:103491; and (4) Dinnes J, Davenport C. Do we have informed consent for asymptomatic COVID‐19 testing in schools? BMJ Opinion. Available at https://blogs.bmj.com/bmj/2021/03/16/do‐we‐have‐informed‐consent‐for‐asymptomatic‐testing‐in‐schools/, 2021 [https://blogs.bmj.com/bmj/2021/03/16/do‐we‐have‐informed‐consent‐for‐asymptomatic‐testing‐in‐schools/, 2021]. Yemisi Takwoingi* is a member of the Cochrane Editorial Board, and an Editor with Cochrane Infectious Diseases and the Cochrane DTA Editorial Team. She was not involved in the editorial process for this review. Clare Davenport* is the Contact Editor for the Cochrane DTA Editorial Team. She was not involved in the editorial process for this review. Mariska MG Leeflang (MML) is an Associate Professor at Academisch Medisch Centrum, and Editor and member of the DTA Editorial Team. She was not involved in the editorial process for this review. MMGL declares a grant from Cochrane for finalising the DTA Handbook, of which she is an active proponent, and royalties from the sale of the Handbook; personal payment. René Spijker (RS) is employed as an Information Specialist for three days per week at Amsterdam UMC. For two days per week, she is seconded to Cochrane Netherlands, which is hosted by the Universitair Medisch Centrum Utrecht. She was not involved in the editorial process for this review. RS declares that the Dutch Cochrane Centre (DCC) has received grants for performing commissioned systematic reviews. In no situation, the commissioner had any influence on the results of the work. Sarah Berhane* is employed as a medicial statistician via grant funding from NIHR Birmingham Biomedical Research Centre to the University of Birmingham. Ann Van den Bruel: none known. Devy Emperador: is employed by FIND, with funding from FCDO and CAN. FIND is a global non‐for‐profit product development partnership and WHO Diagnostic Collaboration Centre. It is FIND’s role to accelerate access to high‐quality diagnostic tools for low‐resource settings and this is achieved by supporting both research and development and access activities for a wide range of diseases, including COVID‐19. FIND has several clinical research projects to evaluate multiple new diagnostic tests against published Target Product Profiles that have been defined through consensus processes. These studies are for diagnostic products developed by private sector companies who provide access to know‐how, equipment/reagents, and contribute through unrestricted donations as per FIND policy and external SAC review (i.e. these companies donate these tests to FIND for free for Find‐sponsored research studies). Ingrid Arevalo‐Rodriguez: none known. Miriam Mateos‐Haro: none known. Agustin Ciapponi works as a health professional at Servicio de Medicina Familiar y Comunitaria, Hospital Italiano de Buenos Aires, Argentina. Diana Buitrago‐Garcia: none known. *Jonathan Deeks, Jacqueline Dinnes, Yemisi Takwoingi, Clare Davenport and Sarah Berhane are supported by the NIHR Birmingham Biomedical Research Centre. This paper presents independent research supported by the NIHR Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free